Drospifem 20, 28 tablets — Made in Germany — Free Delivery

Product description

Drospifen 20 tablets are indicated for oral contraception.

Structure

Active ingredients: ethinylestradiol, drospirenone;

• 1 active pink tablet contains 0.02 mg ethinylestradiol and 3 mg drospirenone;
• 1 white placebo tablet does not contain active substances;

Excipients:

• 1 active tablet contains lactose, corn starch, maltodextrin, magnesium stearate, Opadry 10A240000 pink (hypromellose, talc, titanium dioxide (E 171), polysorbate 80, iron oxide red (E172)).
• 1 placebo tablet contains lactose, corn starch, maltodextrin, magnesium stearate, white mixture for film coating (hypromellose, lactose, titanium dioxide (E 171), macrogol 4000, sodium)).

Contraindications

The presence or risk of developing venous thromboembolism (VTE).

The presence or risk of developing arterial thromboembolism (ATE).

Present or history of severe liver disease before liver function tests return to normal.

Severe renal failure or acute renal failure.

Current or history of liver tumors (benign or malignant). Or suspected malignant tumors (for example, of the genitals or mammary glands), dependent on sex hormones.

Vaginal bleeding of unknown etiology.

Concomitant use with drugs containing ombitasvir / paritaprevir / ritonavir and dazabuvir.

Hypersensitivity to active substances or to any of the components of the drug.

Mode of application

The tablets should be taken at about the same time every day, with a small amount of liquid if necessary, in the sequence indicated on the blister pack. Take 1 tablet daily for 28 consecutive days. Taking pills from each next package should begin the next day after the end of the previous package. Menstrual bleeding usually occurs 2-3 days after you start taking the placebo pills and does not necessarily end before you start taking the pills from the new package.

Application features

Pregnant

The use is contraindicated.

Children

The drug Drospifem 20 is indicated for use as directed by a doctor only after the onset of persistent menstruation.

Drivers

Does not affect.

Overdose

There is still no evidence of an overdose of the drug Drospifem 20. As the general experience with COCs shows, overdose may cause nausea, vomiting and withdrawal bleeding. Withdrawal bleeding can be observed in girls even before the onset of menarche in case of unintentional / accidental use of the drug. There is no specific antidote; treatment must be symptomatic.

Side effects

Mental disorders: emotional lability.

From the nervous system: headache.

From the gastrointestinal tract: nausea.

From the reproductive system and mammary glands: breast tenderness, metrorrhagia, amenorrhea.

Interaction

The information on the medicinal product used simultaneously should be consulted to identify potential interactions.

Interactions are possible with drugs that induce microsomal enzymes. This can lead to an increase in the clearance of sex hormones, which, in turn, can cause breakthrough bleeding and / or loss of contraceptive effectiveness.

In patients with renal insufficiency, the simultaneous use of drospirenone and ACE inhibitors or nonsteroidal anti-inflammatory drugs does not significantly affect the level of potassium in the blood serum. However, the simultaneous use of the drug Drospifem 20 and aldosterone antagonists or potassium-sparing diuretics has not been studied. In this case, it is necessary to study the level of potassium in the blood serum during the first cycle of taking the drug.

Storage conditions

Keep out of the reach of children in its original packaging at a temperature not exceeding 30 ° C.

Shelf life is 3 years.